Company
OBI Pharma, Inc.
Headquarters: Taipei, Taiwan
CEO: Dr. Michael N. Chang PH.D.
Market Cap
TW$16.57 Billion
TWD as of Jan. 1, 2025
US$504.9 Million
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
OBI Pharma, Inc., a bio-pharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor carbohydrate antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immuno-oncology drug; OBI-888, a passive immunotherapy monoclonal antibody designed for targeting Globo H; OBI-999, an antibody drug conjugate; OBI-898 SSEA4, a passive immunity monoclonal antibody; OBI-998 SSEA4, an antibody small molecule drug complex, which targets toxic drugs to malignant tumors; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a clostridium botulinum toxin. The company was founded in 2002 and is based in Taipei, Taiwan.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
OBI Pharma, Inc. has the following listings and related stock indices.
Stock: TWSE: 4174 wb_incandescent